Page 3 - Juno Diagnostics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Humans continue to evolve with the emergence of new genes

/PRNewswire/ -- Juno Diagnostics™ (JunoDx™), a company focused on bringing vital health information to patients by improving access, affordability, and...

/PRNewswire/ -- Juno Diagnostics™ (JunoDx™), a company focused on bringing vital health information to patients by improving access, affordability, and...

up-and-comer has keyed in on a rising star in the biotech world. Ellen Hukkelhoven, an analyst at $8.8 billion Perceptive, presented at Wednesday's Sohn Conference about BridgeBio, the firm's flagship hedge fund's third biggest position, revealing how the company matched up "perfectly" with what Perceptive looks for in a biotech investment. Hukkelhoven, who has a doctorate in molecular biology, explained that the firm looks for companies where the science drives decisions, not the money. While it might seem intuitive that biotech companies are led by the scientists in the lab, Hukkelhoven ex...

The round was led by the Perceptive Xontogeny Venture (PXV) Fund. The company intends to use the funds to support clinical validation studies, product development, and commercial launch of its product offerings for noninvasive prenatal testing (NIPT). Led by Dirk van den Boom, Founder and Chief Executive Officer, Mathias Ehrich M.D., Chief Scientific Officer, and Jim Chauvapun, Chief Operations Officer, Juno Diagnostics is developing genetic testing solutions to improve access to vital health information. The company’s lead product is an NIPT solution that simplifies sample collection and ...